13F Holdings
中文EN

DRTS Alpha Tau Medical Ltd. Annual reports only

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1871321 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-34.3%
TTM EPS YoY-17.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-61.0%
ROA-44.4%
ROIC (approx.)-58.7%
Asset turnover—

Leverage & solvency

Liabilities / assets27.0%
Debt / equity0.00x
Current ratio7.45x
Interest coverage-121.87x

Cash quality & payout

Operating cash flow / net income0.63x
Accruals ratio-16.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$32.06M$27.02M$26.42M$20.89M$11.45M
SG&A expense$8.36M$6.67M$7.33M$10.27M$1.86M
Operating income-$42.29M-$36.04M-$35.68M-$32.14M-$13.79M
Interest expense$347,000$303,000$75,000——
Pretax income-$42.51M-$31.74M-$29.14M-$33.74M-$27.26M
Income tax$121,000$6,000$16,000$20,000$7,000
Net income-$42.63M-$31.75M-$29.16M-$33.76M-$27.27M
EBITDA-$41.06M-$34.94M-$34.61M-$31.16M-$13.01M
EPS (basic)-0.53-0.45-0.42-0.53-0.67
EPS (diluted)-0.53-0.45-0.42-0.53-0.67
Weighted avg. shares (diluted)80.58M69.93M69.38M63.53M40.53M
Balance sheet
Cash & equivalents$12.20M$13.72M$12.66M$6.69M$23.85M
Short-term investments$60.92M$45.88M$69.13M$98.69M$8.08M
Current assets$78.30M$64.23M$85.76M$106.48M$32.64M
PP&E, net$19.66M$13.93M$12.80M$7.47M$7.55M
Total assets$105.65M$86.20M$107.39M$120.15M$42.22M
Current liabilities$10.51M$8.68M$7.10M$4.34M$4.41M
Total liabilities$28.55M$23.54M$22.91M$14.49M$23.03M
Shareholders' equity$77.10M$62.67M$84.47M$105.66M-$34.78M
Shares outstanding88.01M70.38M69.67M69.11M40.53M
Cash flow statement
Operating cash flow-$26.68M-$19.78M-$17.96M-$23.88M-$11.81M
Capital expenditure$6.08M$2.24M$6.40M$904,000$2.93M
Free cash flow-$32.76M-$22.02M-$24.36M-$24.78M-$14.74M
Investing cash flow-$20.59M$20.77M$18.68M-$89.94M$19.27M
Financing cash flow$45.77M$25,000$5.30M$96.91M$111,000
Depreciation & amortization$1.23M$1.10M$1.07M$979,000$776,000
Stock-based compensation$10.62M$9.92M$7.93M$6.75M$812,000

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.